# The Effect of NAC on Lung Function and CT Mucus Score

> **NCT03822637** · PHASE4 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 4 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** n-acetylcystine + albuterol
- **DRUG:** 0.9% saline + albuterol

## Key facts

- **NCT ID:** NCT03822637
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-20
- **Primary completion:** 2025-02-21
- **Final completion:** 2025-02-21
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study was terminated due to COVID restrictions and funding challenges. The study was then simplified and redesigned as the TEAM study (NCT06152653).
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822637, "The Effect of NAC on Lung Function and CT Mucus Score". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03822637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*